877 related articles for article (PubMed ID: 29656345)
1. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
Sharma P
Curr Treat Options Oncol; 2018 Apr; 19(5):22. PubMed ID: 29656345
[TBL] [Abstract][Full Text] [Related]
2. Biology and Management of Patients With Triple-Negative Breast Cancer.
Sharma P
Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
[TBL] [Abstract][Full Text] [Related]
3. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
Anders CK; Abramson V; Tan T; Dent R
Am Soc Clin Oncol Educ Book; 2016; 35():34-42. PubMed ID: 27249684
[TBL] [Abstract][Full Text] [Related]
4. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
5. Targeted Therapies for Triple-Negative Breast Cancer.
Lyons TG
Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
[TBL] [Abstract][Full Text] [Related]
6. Optimizing chemotherapy in triple-negative breast cancer: the role of platinum.
Telli M
Am Soc Clin Oncol Educ Book; 2014; ():e37-42. PubMed ID: 24857126
[TBL] [Abstract][Full Text] [Related]
7. Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.
Spugnesi L; Gabriele M; Scarpitta R; Tancredi M; Maresca L; Gambino G; Collavoli A; Aretini P; Bertolini I; Salvadori B; Landucci E; Fontana A; Rossetti E; Roncella M; Naccarato GA; Caligo MA
Genes Chromosomes Cancer; 2016 Dec; 55(12):915-924. PubMed ID: 27328445
[TBL] [Abstract][Full Text] [Related]
8. Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.
Jin J; Zhang W; Ji W; Yang F; Guan X
Cancer Biol Ther; 2017 Jun; 18(6):369-378. PubMed ID: 28494179
[TBL] [Abstract][Full Text] [Related]
9. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
Tazzite A; Jouhadi H; Benider A; Nadifi S
Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
[TBL] [Abstract][Full Text] [Related]
10. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
[TBL] [Abstract][Full Text] [Related]
11. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
12. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers of DNA Repair and Related Pathways: Significance of Treatment in Triple-Negative Breast Cancer.
Guo W; Lin L; He X; He F; Wang C; Chen N; Wang Y
Crit Rev Oncog; 2017; 22(5-6):427-437. PubMed ID: 29604922
[TBL] [Abstract][Full Text] [Related]
14. Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer.
Stover DG; Winer EP
Breast; 2015 Nov; 24 Suppl 2():S132-5. PubMed ID: 26255198
[TBL] [Abstract][Full Text] [Related]
15. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
Evans KW; Yuca E; Akcakanat A; Scott SM; Arango NP; Zheng X; Chen K; Tapia C; Tarco E; Eterovic AK; Black DM; Litton JK; Yap TA; Tripathy D; Mills GB; Meric-Bernstam F
Clin Cancer Res; 2017 Nov; 23(21):6468-6477. PubMed ID: 29093017
[No Abstract] [Full Text] [Related]
16. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
17. Homologous recombination deficiency in triple negative breast cancer.
Belli C; Duso BA; Ferraro E; Curigliano G
Breast; 2019 Jun; 45():15-21. PubMed ID: 30818144
[TBL] [Abstract][Full Text] [Related]
18. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U
BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers.
Domagala P; Jakubowska A; Jaworska-Bieniek K; Kaczmarek K; Durda K; Kurlapska A; Cybulski C; Lubinski J
PLoS One; 2015; 10(6):e0130393. PubMed ID: 26083025
[TBL] [Abstract][Full Text] [Related]
20. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E
Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
